J&J kicks off final study of single-shot Covid-19 vaccine in 60,000 volunteers

Johnson & Johnson on Wednesday kicked off a final 60,000-person trial of a single-shot Covid-19 vaccine that potentially would simplify distribution of millions of doses compared with leading rivals using two doses.The company expects results of the Phase III trial by year end or early next year, Dr. Paul Stoffels, J&J's chief scientific officer, said in a joint press conference with officials from the National Institutes of Health and the Trump administration.